University of Thessaly (UTH)
Αλλαγές και τάσεις διαχρονικά στην επιδημιολογία και αντιμετώπιση των λοιμώξεων του κατώτερου αναπνευστικού συστήματος σε παιδιά στην Κεντρική Ελλάδα
Abstract
dc:descriptionRespiratory tract infections are one of the most common cause for which parents seek medical advice. Recently the interest of researchers has focused on lower respiratory tract infections (LRTI) as they are responsible for a greater number of visits to health care units and are characterized by a higher rate of complications. The most interesting clinical forms of LRTI are bronchiolitis and pneumonia. Acute viral bronchiolitis is a leading cause of illness and hospitalization in infants and can be severe in some cases. Research into the variation in treatment and outcomes of bronchiolitis across different settings has led to clinical practice guidelines. Evidence-based reviews have suggested a limited role due to lack of efficacy for routine use of bronchodilators and corticosteroids for the treatment of acute bronchiolitis. In this 11-year study of acute bronchiolitis in infants admitted in the Department of Pediatrics, in a tertiary Medical Center in Central Greece, a statistically significant reduction of the use of bronchodilators, adrenaline, corticosteroids and antibiotics was noticed (χ2 for trend p<0,001). Furthermore, an increase, during the period of the study, in the use of inhaled hypertonic NS 3% and nasal CPAP was observed (χ2 for trend p<0,001). Pneumonia still represents a major disease burden in children in industrialized countries. Almost 20%–60% of cases of community-acquired pneumonia (CAP) are thought to be pneumococcus-related, but only a small proportion of pneumonia is diagnosed as pneumococcal in clinical practice. The implementation of both the 7-valent polysaccharide pneumococcal conjugate vaccine (PCV7) and 13-valent polysaccharide pneumococcal vaccine (PCV13) has markedly reduced the incidence of pneumonia in several countries. Still, the empyema – complicated pneumonia, represents a major burden in the pediatric population. Few studies, mostly conducted within the first 2 years of widespread use of PCV13 have addressed the changes of the serotypes responsible for empyema in children. In this 8-year study, which essentially involves the first five years of widespread use of the 13-valent pneumococcal vaccine in Greece, a reduction of serotype 19A related cases of empyema was noticed. A significant reduction in the hospital admissions of CAP with moderate or large in size effusion was also observed (χ2 for trend p=0,009). Serotype 3 was the only PCV13 serotype that has persisted in children with empyema (χ2 for trend p=0,031) despite vaccination with PCV13 either fully with a 3+1 schedule (n=3) or with one booster dose at the age of 21 months (n=1). In contrast to the protection against parapneumonic empyema provided by PCV13 for the additional serotypes included in the vaccine, similar evidence for serotype 3 is lacking. Continued surveillance will further clarify the PCV13 impact on CAP with pleural effusion and shed light to the potential emergence of replacement non-PCV13 serotypes.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Michoula, Aspasia
- Μιχούλα, Ασπασία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38564